BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33871406)

  • 1. An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
    Mukai Y; Wakamoto A; Hatsuyama T; Yoshida T; Sato H; Fujita A; Inotsume N; Toda T
    Ther Drug Monit; 2021 Dec; 43(6):772-779. PubMed ID: 33871406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
    Xiong X; Zhang Y; Wang Z; Zhou C; Yang P; Du X; Yang L; Liu W
    Clin Chim Acta; 2022 Feb; 527():1-10. PubMed ID: 34999058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.
    Ishikawa E; Yokoyama Y; Chishima H; Kuniyoshi O; Sato I; Nakaya N; Nakajima H; Kimura M; Hakamata J; Suehiro N; Nakada H; Ikemura S; Jibiki A; Kawazoe H; Muramatsu H; Suzuki S; Nakamura T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 May; 1199():123245. PubMed ID: 35436724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib.
    Veerman GDM; Lam MH; Mathijssen RHJ; Koolen SLW; de Bruijn P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Apr; 1113():37-44. PubMed ID: 30889498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
    Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
    J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer.
    Zhou L; Wang S; Chen M; Huang S; Zhang M; Bao W; Bao A; Zhang P; Guo H; Liu Z; Xie G; Gao J; Wu Z; Lou Y; Fan G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1175():122752. PubMed ID: 33991955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run.
    van Veelen A; van Geel R; Schoufs R; de Beer Y; Stolk LM; Hendriks LEL; Croes S
    Biomed Chromatogr; 2021 Dec; 35(12):e5224. PubMed ID: 34363425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.
    Arai S; Takeuchi S; Fukuda K; Taniguchi H; Nishiyama A; Tanimoto A; Satouchi M; Yamashita K; Ohtsubo K; Nanjo S; Kumagai T; Katayama R; Nishio M; Zheng MM; Wu YL; Nishihara H; Yamamoto T; Nakada M; Yano S
    J Thorac Oncol; 2020 May; 15(5):752-765. PubMed ID: 31972351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of intracellular anlotinib, osimertinib, afatinib and gefitinib accumulations in human brain microvascular endothelial cells by liquid chromatography/tandem mass spectrometry.
    Ma Z; Lu S; Zhou H; Zhang S; Wang Y; Lin N
    Rapid Commun Mass Spectrom; 2021 Jan; 35(1):e8955. PubMed ID: 32990383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
    Hayashi H; Kita Y; Iihara H; Yanase K; Ohno Y; Hirose C; Yamada M; Todoroki K; Kitaichi K; Minatoguchi S; Itoh Y; Sugiyama T
    Biomed Chromatogr; 2016 Jul; 30(7):1150-1154. PubMed ID: 26525154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
    Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T
    Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients.
    Chen GY; Liang SK; Wei YF; Weng TI; Chen KY
    Anal Biochem; 2023 May; 669():115115. PubMed ID: 36931580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of UPLC-MS/MS method for the simultaneous quantification of anaplastic lymphoma kinase inhibitors, alectinib, ceritinib, and crizotinib in Wistar rat plasma with application to bromelain-induced pharmacokinetic interaction.
    Maher HM; Almomen A; Alzoman NZ; Shehata SM; Alanazi AA
    J Pharm Biomed Anal; 2021 Sep; 204():114276. PubMed ID: 34325247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum: Erratum.
    Ther Drug Monit; 2022 Apr; 44(2):357. PubMed ID: 35292612
    [No Abstract]   [Full Text] [Related]  

  • 16. Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS.
    Li Y; Meng L; Ma Y; Li Y; Xing X; Guo C; Dong Z
    Molecules; 2022 Jul; 27(14):. PubMed ID: 35889345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
    Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients.
    Zhao J; Yan D; Li Y; Xu X; Li F; Zhang S; Jin J; Qiu F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Apr; 1237():124100. PubMed ID: 38547701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.